Edwards Lifesciences receives CEO Cancer Gold StandardTM accreditation
Edwards Lifesciences (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for their own employees and their covered family members.